CRISPR Post-Earnings: Short Sellers Stay Put as Street Weighs the Print

CRSP has cleared its November 3 earnings hurdle, and the market's immediate verdict was unenthusiastic: the stock fell 2.8% on the week to $49.99, even as most gene-editing peers held flat or gained.

The short position has stabilised rather than retreated further after the print. Short interest now sits at 16.2% of free float, down just 3% on the week and roughly 22% below October's peak, continuing the structured unwind documented before results. That unwinding trend appears to have stalled post-earnings: the daily readings show very little movement over the past three sessions, suggesting shorts who intended to cover ahead of the print have largely done so, and those who remain are sitting tight. Borrow conditions give them no particular urgency to move: the cost to borrow edged up to 0.55%, still a low figure, and availability is comfortable at 128%, meaning roughly 1.3 shares remain available to borrow for every share already lent out. The 52-week trough on availability was 0.23%, so the lending market is nowhere near stressed. The ORTEX short score reads 76.8, little changed over the past two weeks, ranking in the 6th percentile for short pressure across the universe. That is a high absolute score for a stock carrying this level of float-short, which reflects the size of the position rather than any sign of imminent squeeze.

Options positioning has shifted meaningfully since the earnings-preview note. The put/call ratio was at its most call-heavy in months before the print. It has since edged back toward neutral at 0.51, fractionally below its 20-day mean of 0.53, and nearly 1.3 standard deviations below average in the z-score. The bullish pre-earnings options lean did not translate into a price gain, and the PCR's return toward the mean suggests that call-buying interest has not been renewed post-print.

The Street is broadly constructive but with diminishing conviction around the current price. Wells Fargo trimmed its target from $75 to $70 this week, maintaining Equal-Weight, a signal that one of the more cautious voices on the stock sees the downside case as slightly more weighted after the results. Needham held at Buy with an $82 target, and UBS, which initiated coverage last month at Neutral with a $52 target, sits closest to the current price among the analysts on record. The mean target across the analyst group is $85.74, implying substantial upside from $49.99, but that gap is partly a function of the Buy-side analysts anchoring higher while the neutral camp anchors near spot. Bulls cite the CTX310 cardiovascular programme, where ANGPTL3 reductions of 78.6% at one year post-dose look durable, plus roughly $2.1 billion in estimated year-end cash that buys meaningful runway. Bears point to IP uncertainty around the CRISPR/Cas9 patent position, clinical risk across multiple early-stage programmes, and the dilution risk implicit in a company still burning cash. The price-to-book multiple of 3.45 has contracted about 8% over the past month, consistent with the stock's slide.

The CEO sold $2.4 million of stock on October 19 in a discretionary transaction, not under a 10b5-1 plan, alongside a tax-related exercise earlier in the month. The 90-day net insider position is minus $4.9 million. Those are not large numbers relative to a $4.8 billion market cap, but the absence of open-market buying from management, in a stock sitting at the lower end of its recent range with an apparent fundamental catalyst in CTX310, is worth noting. Among the institutional base, ARK Investment Management holds 9.46 million shares at roughly 9.8% of shares outstanding, adding 545,000 shares in the quarter to September 30. BlackRock added 669,000 shares over the same period to reach 8.6%. State Street added 703,000 shares. The buying from these large holders provides a demand floor, though ARK's 13G filing from April shows a disclosed stake of 11.79% that has since modestly declined to 9.78% per the latest 13F, a reduction worth watching in future filings.

Retail attention has spiked well above its recent baseline: the Wikipedia views signal shows a z-score of 2.25 relative to the prior 90 days, one of the stronger retail-attention readings across the coverage universe. That uptick aligns with the earnings release and CTX310 coverage, but attention spikes without a price follow-through often fade quickly.

The next scheduled earnings event is February 11, 2027, leaving 99 days for the pipeline narrative, particularly any further CTX310 cohort data or Casgevy sales updates, to either rebuild or erode confidence in the gap between $50 and the analyst consensus.